Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Jurnal Riset Ilmu Kesehatan Umum dan Farmasi Journal of Natural Products and Drug Development
Fitria Wahyuning Wulan
Institut Ilmu Kesehatan Bhakti Wiyata Kediri
Health Professions Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
INPATIENT ANTITHROMBOTIC THERAPY FOR MYOCARDIAL INFARCTION : RETROSPECTIVE STUDY Shofiatul Fajriyah; Dilla Salwa Nur Rohmah; Lelly Winduhani Astuti; Fentyana Dwi Rilawati; Fitria Wahyuning Wulan; Esti Ambar Widyaningrum
Jurnal Riset Ilmu Kesehatan Umum dan Farmasi (JRIKUF) Vol. 3 No. 3 (2025): Juli : Jurnal Riset Ilmu Kesehatan Umum dan Farmasi (JRIKUF)
Publisher : LPPM STIKES KESETIAKAWANAN SOSIAL INDONESIA

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.57213/jrikuf.v3i3.762

Abstract

Myocardial infarction (MI), a subtype of coronary heart disease (CHD), is still a major cause of morbidity and mortality around the world. Non-ST-segment elevation MI (NSTEMI) is more common than ST-segment elevation MI (STEMI). Antithrombotic therapy, including antiplatelet and anticoagulant agents, is essential in MI management to prevent thrombus formation and reduce ischemic complications. Although international and national clinical guidelines (PERKI and ACC/AHA) provide recommendations tailored to MI type and patient factors, discrepancies in clinical practice, especially in developing countries, may impact treatment outcomes. This retrospective descriptive study aimed to evaluate the use and appropriateness of antithrombotic therapy in NSTEMI and STEMI patients at Hospital X, Kediri City, in 2018. Data were collected from medical records of hospitalized acute myocardial infarction (AMI) patients. Aspirin combined with clopidogrel was the most commonly used regimen for NSTEMI, whereas STEMI patients frequently received aspirin, clopidogrel, and enoxaparin; fibrinolytics were administered in nine STEMI cases. Dosage evaluation showed compliance with guidelines in NSTEMI patients, while 36.84% of STEMI patients, particularly those receiving enoxaparin, were given incorrect dosages. These findings highlight the need for improved adherence to clinical guidelines to optimize antithrombotic therapy outcomes in MI management
Evaluation of The Rationality of Dengue Hemorrhagic Fever (DHF) Treatment in Inpatients at Rsi Siti Aisyah Madiun in The 2024 Period Djembor Sugeng Walujo; Fitria Wahyuning Wulan; Azrena Tasya Nur Afifah
Journal of Natural Products and Drug Development Vol. 1 No. 1 (2025): Journal of Natural Products and Drug Development
Publisher : CV Media Inti Teknologi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.58723/jnpdd.v1i1.43

Abstract

Background of Study: Drug rationality is an important aspect to ensure the achievement of therapeutic effects and improve the quality of life of patients with the criteria of the right drug, right dose, right diagnosis and right indication. Meanwhile, thet use oft a drugt is saidt to bet irrationalt if thet possibilityt of negativet impactst receivedt by thet patientt is greatert than its benefitstt.Aims and Scope of Paper: This study aimst to determine the descriptiont of the rationalityt of Denguet Hemorrhagict Fevert (DHF) treatment in hospitalized patients at RSI Siti Aisyah Madiun in terms of the right drug, right dose, right diagnosis, and right indication.Method: The study used was an observationalt study conductedt retrospectively with univariate analysis and purposive sampling techniques.Results: The use of drugs for Dengue Hemorrhagic Fever (DHF) from the electrolyte fluid group, namely asering infusion 22.56%, RL infusion 33.83%, NS infusion 23.31%, D5 infusion 0.45% 20.30%, and for the antipyretic group, namely paracetamol 100%, for the antiemetic group, namely ondansetron 67.67%, metoclopramide 32.33% while from the supplement and vitamin group, namely curcuma 77.44% and psidii 22.56%. The rationality of drug use includes 100% correct drug, 97.74% correct dose, and 100% correct diagnosis and 100% correct indication.Conclusion: Based on the variables tested, thet rationalityt of the uset of drugs for Dengue Hemorrhagict Fevert (DHF) has met the criteria for rationality of treatment.
Co-Authors Azrena Tasya Nur Afifah Dilla Salwa Nur Rohmah Djembor Sugeng Walujo Esti Ambar Widyaningrum Fentyana Dwi Rilawati Lelly Winduhani Astuti Shofiatul Fajriyah